Russell Investments Group Ltd. Has $106.32 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Russell Investments Group Ltd. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 121,030 shares of the biopharmaceutical company's stock after selling 5,171 shares during the period. Russell Investments Group Ltd. owned approximately 0.11% of Regeneron Pharmaceuticals worth $106,318,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Meyer Handelman Co. grew its position in Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company's stock worth $3,485,000 after purchasing an additional 435 shares during the last quarter. Stifel Financial Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 12.2% in the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company's stock valued at $25,537,000 after acquiring an additional 3,385 shares in the last quarter. LPL Financial LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company's stock valued at $33,522,000 after acquiring an additional 3,479 shares in the last quarter. Cavalier Investments LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 88.6% in the third quarter. Cavalier Investments LLC now owns 4,436 shares of the biopharmaceutical company's stock valued at $3,651,000 after acquiring an additional 2,084 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 32.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company's stock valued at $4,351,000 after acquiring an additional 1,221 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the topic of several analyst reports. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a "buy" rating in a report on Wednesday. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Truist Financial reissued a "buy" rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a report on Tuesday, January 23rd. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $977.77.

Regeneron Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ:REGN traded down $7.48 during trading on Friday, reaching $883.20. The stock had a trading volume of 505,652 shares, compared to its average volume of 431,865. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The business has a fifty day moving average price of $948.00 and a 200-day moving average price of $894.45. The stock has a market cap of $96.94 billion, a P/E ratio of 25.42, a PEG ratio of 2.54 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the firm earned $10.96 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up .6% on a year-over-year basis. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business's stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business's stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bonnie L. Bassler sold 827 shares of the company's stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now owns 1,382 shares of the company's stock, valued at $1,325,338. The disclosure for this sale can be found here. Insiders sold a total of 11,022 shares of company stock worth $10,552,991 over the last ninety days. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.